CEO Hany Massarany said that 2017 will be a pivotal year for the company as it expects to launch the ePlex sample-to-answer system in the US.
GenMark's CEO said that the firm continues to focus on growing the ePlex instrument's global reach and expanding its menu.
Encouraged by positive customer feedback from early installations, the firm is shifting its sales focus to the ePlex system and respiratory pathogen panel.
The test detects 11 viruses and three bacterial pathogens in approximately one hour and requires two minutes of hands-on time.
The company also cut its net loss in the first half of the year to €6.7 million from €12.4 million in the year-ago period.
The ePlex system integrates sample preparation with GenMark's eSensor technology to enable the detection of multiple molecular targets on a single test cartridge.
The high-throughput system is now approved with the firm's Blood Culture ID, Gastrointestinal, Meningitis/Encephalitis, and the previously approved Respiratory Panel.
The firm has also submitted three other assays for special 510(k) clearance on the Torch system.
By focusing on the clinical scenario, a Duke team developed a gene expression-based model to determine whether a patient's disease is bacterial or viral.
The FilmArray Torch has up to 12 modules per system and can process up to 262 patient samples per day using the firm's syndromic panel tests.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.